Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.44 |
| ▸ | CNR1 | P21554 | 5/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3432576 | 0.81 | ELANE (0.54) | ROCK1PKM | |
| SCHEMBL3431965 | 0.80 | NPC1 (0.50) | CNR1CNR2ROCK1PKM | |
| SCHEMBL3431330 | 0.79 | ELANE (0.53) | CNR1CNR2ROCK1 | |
| SCHEMBL3755136 | 0.76 | RAB9A (0.54) | ROCK1PKM | |
| SCHEMBL3430571 | 0.73 | ELANE (0.47) | CNR1ROCK1PKM | |
| SCHEMBL3428314 | 0.73 | TSHR (0.55) | — | |
| SCHEMBL3751996 | 0.73 | RAB9A (0.53) | ROCK1PKM | |
| SCHEMBL3427977 | 0.71 | KCNA5 (0.54) | — | |
| SCHEMBL3427834 | 0.71 | TSHR (0.55) | — | |
| SCHEMBL13671628 | 0.70 | SCN9A (0.53) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | CPT1B, SMN1; SMN2, GYS1 | TRPV1 4732/4885CNR1 2500/4885CNR2 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.